NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $14.66 +1.63 (+12.51%) Closing price 04:00 PM EasternExtended Trading$14.62 -0.04 (-0.29%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arcturus Therapeutics Stock (NASDAQ:ARCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcturus Therapeutics alerts:Sign Up Key Stats Today's Range$12.68▼$15.1750-Day Range$5.75▼$16.9352-Week Range$5.50▼$24.17Volume1.32 million shsAverage Volume766,806 shsMarket Capitalization$416.64 millionP/E RatioN/ADividend YieldN/APrice Target$22.43Consensus RatingModerate Buy Company Overview Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines. The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need. Its pipeline has included mRNA-based treatments for metabolic and genetic disorders, including ornithine transcarbamylase deficiency, as well as programs designed to address cystic fibrosis and other conditions. Arcturus has also developed RNA-based vaccine candidates, including a self-amplifying mRNA COVID-19 vaccine developed in collaboration with CSL. Arcturus was founded in 2013 and has entered into collaborations and licensing arrangements with pharmaceutical companies and other organizations to advance its technologies. The company is led by Joseph E. Payne, who serves as president and chief executive officer. Its activities are primarily focused on research, clinical development and strategic partnerships supporting the development of RNA medicines for patients worldwide.AI Generated. May Contain Errors. Read More Arcturus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreARCT MarketRank™: Arcturus Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 341st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArcturus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArcturus Therapeutics has a consensus price target of $22.43, representing about 53.0% upside from its current price of $14.66.Amount of Analyst CoverageArcturus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcturus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arcturus Therapeutics are expected to decrease in the coming year, from ($3.48) to ($3.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted23.40% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 6.37.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 10.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.18 News SentimentArcturus Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows3 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARCT Stock News HeadlinesArcturus Therapeutics (NASDAQ:ARCT) Rating Lowered to "Sell" at Wall Street ZenOctober 4 at 1:07 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Arcturus Therapeutics (ARCT)October 3 at 12:44 PM | theglobeandmail.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 5 at 1:00 AM | Chaikin Analytics (Ad)Arcturus Therapeutics (NASDAQ:ARCT) Upgraded to Hold at Wall Street ZenSeptember 26, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Arcturus Therapeutics (ARCT), ACADIA Pharmaceuticals (ACAD)September 25, 2026 | theglobeandmail.comArcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup UpgradeSeptember 24, 2026 | marketscreener.comMArcturus raised to Buy at Citi after mid-stage trial data for liver disease drugSeptember 24, 2026 | seekingalpha.comArcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0 Next-Generation mRNA Delivery PlatformSeptember 24, 2026 | marketscreener.comMSee More Headlines ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $6.13 at the beginning of the year. Since then, ARCT shares have increased by 139.2% and is now trading at $14.66. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings results on Friday, August, 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.16. The biotechnology company had revenue of $2.96 million for the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative trailing twelve-month return on equity of 46.54%. Read the conference call transcript. Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' top institutional investors include Versant Capital Management Inc (0.01%). View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2026Today10/05/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ARCT's financial health is in the Green zone, according to TradeSmith. ARCT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARCT CIK1768224 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees111Year Founded2013Price Target and Rating Average Price Target for Arcturus Therapeutics$22.43 High Price Target$41.00 Low Price Target$9.00 Potential Upside/Downside+53.0%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.78 million Net Margins-317.62% Pretax Margin-317.64% Return on Equity-46.54% Return on Assets-36.46% Debt Debt-to-Equity RatioN/A Current Ratio5.88 Quick Ratio5.88 Sales & Book Value Annual Sales$82.03 million Price / Sales5.08 Cash FlowN/A Price / Cash FlowN/A Book Value$7.53 per share Price / Book1.95Miscellaneous Outstanding Shares28,420,000Free Float23,364,000Market Cap$416.64 million OptionableOptionable Beta2.48 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ARCT) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts